TD Cowen raised the firm’s price target on Praxis Precision (PRAX) to $251 from $61 and keeps a Buy rating on the shares. Praxis announced positive results from both Phase 3 Essential3 ET studies of ulixacaltamide, showing a statistically significant mADL 11 improvement. vs. placebo in study 1 and superior maintenance of effect in study 2, the analyst tells investors in a research note. These results were unexpectedly positive, strong and consistent, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $360 from $85 at Truist
- Optimistic Buy Rating for Praxis Precision Medicines Amid Positive Phase 3 Results and Strategic Advancements
- Praxis Precision price target raised to $275 from $76 at Baird
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- Buy Rating Affirmed for Praxis Precision Medicines Following Positive Phase 3 Study Results